Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 07, 2021 16:05 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference

BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer...
August 27, 2021 07:45 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting

Initial findings from an ongoing study demonstrated that a 0.3 mg/kg dose of ALRN-6924 has been very well tolerated and resulted in p53-mediated induction of the cell cycle inhibitor p21 in normal...
August 11, 2021 16:20 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

Initiated Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC); first interim safety data expected at end...
July 08, 2021 08:15 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021

BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer...
July 01, 2021 08:00 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1b trial anticipated to enroll 60 patients with advanced p53-mutated NSCLC undergoing chemotherapy with first-line carboplatin plus pemetrexedStudy will evaluate proportion of treatment cycles...
June 24, 2021 07:00 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics to be Added to the Russell Microcap® Index

BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer...
May 19, 2021 07:00 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities

-- Fireside chat, moderated by Soumit Roy, Ph.D. of JonesTrading, will be held on Wednesday, May 26, 2021 at 11:00 am ET -- -- Featured speakers will include hematologist Alan List, M.D....
May 11, 2021 16:18 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Progressing ALRN-6924: on track to initiate Phase 1b randomized placebo-controlled trial in patients with p53-mutated non-small cell lung cancer in 2nd quarter 2021 with early interim read-out...
March 24, 2021 16:36 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights

2020 marked a year of successful evolution to a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients -- Advancing selective...
March 04, 2021 08:30 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference

WATERTOWN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate...